Difference between revisions of "Team:SCUT-China"
| (9 intermediate revisions by 3 users not shown) | |||
| Line 20: | Line 20: | ||
position: absolute; | position: absolute; | ||
width: 35%; | width: 35%; | ||
| − | top: | + | top: 30%; |
} | } | ||
#picLeft img { | #picLeft img { | ||
| Line 29: | Line 29: | ||
#picRight { | #picRight { | ||
position: absolute; | position: absolute; | ||
| − | width: | + | width: 40%; |
| − | top: | + | top:32%; |
| − | left: | + | left: 62%; |
} | } | ||
#picRight img { | #picRight img { | ||
| Line 52: | Line 52: | ||
background-repeat:no-repeat; | background-repeat:no-repeat; | ||
left:50%; | left:50%; | ||
| − | top: | + | top:80%; |
position:absolute; | position:absolute; | ||
transition: 0.3s ease; | transition: 0.3s ease; | ||
| Line 82: | Line 82: | ||
position: relative; | position: relative; | ||
margin: 30px auto; | margin: 30px auto; | ||
| − | padding: | + | padding: 0px; |
| + | box-sizing:content-box; | ||
} | } | ||
#overviewArea h2 { | #overviewArea h2 { | ||
| Line 90: | Line 91: | ||
} | } | ||
#overviewArea p { | #overviewArea p { | ||
| − | margin: | + | margin:20px auto; |
width:70%; | width:70%; | ||
text-indent: 2em; | text-indent: 2em; | ||
| Line 134: | Line 135: | ||
<div id="indexContainer"> | <div id="indexContainer"> | ||
<div id="picArea"> | <div id="picArea"> | ||
| − | <div id="picLeft"> <img id=" | + | <div id="picLeft"> <img id="img_Left" src="https://static.igem.org/mediawiki/2015/7/7f/2015-SCUT-China-home-left.gif" /> </div> |
| − | <img id="home-heart" src="https://static.igem.org/mediawiki/2015/ | + | <img id="home-heart" src="https://static.igem.org/mediawiki/2015/4/4f/2015-SCUT-China-home-middle.gif" /> |
| − | <div id="picRight"> <img id="img_Right" src="https://static.igem.org/mediawiki/2015/ | + | <div id="picRight"> <img id="img_Right" src="https://static.igem.org/mediawiki/2015/e/ed/2015-SCUT-China-home-right.gif" /> </div> |
<div id="btn-down"></div> | <div id="btn-down"></div> | ||
<div class="bottom-line"></div> | <div class="bottom-line"></div> | ||
| Line 142: | Line 143: | ||
<div id="overviewArea"> | <div id="overviewArea"> | ||
<h2>Overview</h2> | <h2>Overview</h2> | ||
| − | <p>According to the data from WHO, cardiovascular diseases are the main leading cause of death globally. Cyclic guanosine monophosphate (cGMP) is a critical second messenger molecule.It can transduce nitric-oxide and natriuretic-peptide-coupled signaling and remit the myocardial hypertrophy by relaxing the blood vessels. This summer, we tried to use synthetic biology to modify the cGMP metabolic pathway in a human cell line.We hope that our work would provide the proof of principle for future gene therapy.</p> | + | <p>According to the data from WHO, cardiovascular diseases are the main leading cause of death globally. Cyclic guanosine monophosphate (cGMP) is a critical second messenger molecule.It can transduce nitric-oxide (NO) and natriuretic-peptide-coupled signaling and remit the myocardial hypertrophy by relaxing the blood vessels. This summer, we tried to use synthetic biology to modify the cGMP metabolic pathway in a human cell line.We hope that our work would provide the proof of principle for future gene therapy.</p> |
<img id="overviewPic" src="https://static.igem.org/mediawiki/2015/4/49/2015-SCUT-China-home-overview.png"/> | <img id="overviewPic" src="https://static.igem.org/mediawiki/2015/4/49/2015-SCUT-China-home-overview.png"/> | ||
<p>Soluble guanylate cyclase (sGC) is an enzyme that synthesize cGMP from GTP. We up-regulate sGC by overexpressing its α and β subunits in a mammalian cell line. However, elevated levels of cGMP leads to the feed-back expression of PDE5a, a cGMP-specific phosphodiesteras that degrades cGMP. Thus, we further modified the pathway by silencing the PDE5a. To achieve controllable up-regulation of cGMP level in the cell, we designed a hypoxia-inducible operon, HRE, as a switch to up regulate cGMP only in hypoxia situation.</p> | <p>Soluble guanylate cyclase (sGC) is an enzyme that synthesize cGMP from GTP. We up-regulate sGC by overexpressing its α and β subunits in a mammalian cell line. However, elevated levels of cGMP leads to the feed-back expression of PDE5a, a cGMP-specific phosphodiesteras that degrades cGMP. Thus, we further modified the pathway by silencing the PDE5a. To achieve controllable up-regulation of cGMP level in the cell, we designed a hypoxia-inducible operon, HRE, as a switch to up regulate cGMP only in hypoxia situation.</p> | ||
| Line 161: | Line 162: | ||
$("#btn-down").click(function(){ | $("#btn-down").click(function(){ | ||
| − | $("html,body").animate({scrollTop:$("#overviewArea").offset().top- | + | $("html,body").animate({scrollTop:$("#overviewArea").offset().top-90},1000); |
}); | }); | ||
Latest revision as of 02:17, 19 September 2015
Loading
Overview
According to the data from WHO, cardiovascular diseases are the main leading cause of death globally. Cyclic guanosine monophosphate (cGMP) is a critical second messenger molecule.It can transduce nitric-oxide (NO) and natriuretic-peptide-coupled signaling and remit the myocardial hypertrophy by relaxing the blood vessels. This summer, we tried to use synthetic biology to modify the cGMP metabolic pathway in a human cell line.We hope that our work would provide the proof of principle for future gene therapy.
Soluble guanylate cyclase (sGC) is an enzyme that synthesize cGMP from GTP. We up-regulate sGC by overexpressing its α and β subunits in a mammalian cell line. However, elevated levels of cGMP leads to the feed-back expression of PDE5a, a cGMP-specific phosphodiesteras that degrades cGMP. Thus, we further modified the pathway by silencing the PDE5a. To achieve controllable up-regulation of cGMP level in the cell, we designed a hypoxia-inducible operon, HRE, as a switch to up regulate cGMP only in hypoxia situation.